ASH 2020 | Mosunetuzumab for chemotherapy-intolerant DLBCL
Adam Olszewski, MD, Brown University, Providence, RI, shares the preliminary results of the ongoing Phase I/II trial (NCT03677154) assessing the safety and efficacy of mosunetuzumab in patients with diffuse large B-cell lymphoma (BLBCL) who are intolerant to chemotherapy. Results show good efficacy, where 60% of patients achieved a response, of which 45% showed sustained complete response (CR). However, longer follow-up is required to assess the durability of CR. Mosunetuzumab showed a good safety profile, where 20% of patients exhibited grade 1, reversible cytokine release syndrome (CRS). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to the institution: Genentech/Roche, TG Therapeutics, Spectrum Pharmaceuticals
Research support: Adaptive Biotechnologies
